EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer

Courtney T S Kureshi, Michael J Walsh, Rakeeb Kureshi, Victoire Cardot-Ruffino, Dennis A Agardy, Lestat R Ali, James M Dougan, Li Qiang, Jiao Shen, Chong Zuo, Patrick J Lenehan, S Jennifer Wang und 24 weitere

Cancer Cell · 2026-07 · 44 (7) · 1381-1400.e9

DOI: 10.1016/j.ccell.2026.04.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2026-07. Verfasst von Courtney T S Kureshi und 35 weiteren Autor:innen. Beteiligte Einrichtung: Harvard Medical School Program in Immunology, Boston, MA, USA; Massachusetts General Hospital, Department of Medicine, Division of Gastroenterology, …. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Dendritic Cells, CD4-Positive T-Lymphocytes. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIAID NIH HHS, Hale Family Center for Pancreatic Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsCarcinoma, Pancreatic DuctalDendritic CellsCD4-Positive T-LymphocytesAnimalsHumansMiceInterferon-gammaCell Line, TumorCTLA-4 AntigenImmunotherapyFemaleMice, Inbred C57BLImmune Checkpoint InhibitorsCD8-Positive T-Lymphocytes

Stichwörter der Autor:innen

CD4(+) T cellsCTLA-4IFNγPD-1PDACSTINGcDC2dendritic cellsimmune checkpoint blockadepancreatic cancer

Substanzen

Interferon-gammaCTLA-4 AntigenImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Harvard Medical School Program in Immunology, Boston, MA, USA; Massachusetts General Hospital, Department of Medicine, Division of Gastroenterology, Boston, MA, USA; Dana-Farber Cancer Institute, Department of Cancer Im…
  • Massachusetts General Hospital, Department of Medicine, Division of Gastroenterology, Boston, MA, USA; Dana-Farber Cancer Institute, Department of Cancer Immunology & Virology, Boston, MA, USA; Harvard Medical School Pr…
  • Harvard Medical School Program in Immunology, Boston, MA, USA; Dana-Farber Cancer Institute, Department of Cancer Immunology & Virology, Boston, MA, USA.
  • Dana-Farber Cancer Institute, Department of Cancer Immunology & Virology, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
  • Dana-Farber Cancer Institute, Department of Cancer Immunology & Virology, Boston, MA, USA.
  • Massachusetts General Hospital, Department of Medicine, Division of Gastroenterology, Boston, MA, USA; Dana-Farber Cancer Institute, Department of Cancer Immunology & Virology, Boston, MA, USA; Harvard Medical School, B…

Förderung

  • NCI NIH HHS
  • NIAID NIH HHS
  • Hale Family Center for Pancreatic Cancer Research
  • Sky Foundation Inc
  • Foundation for the National Institutes of Health
  • Bristol-Myers Squibb Company
  • Harvard Medical School Ludwig Center
  • German Research Foundation

Zitieren

APA

Kureshi, C. T. S., Walsh, M. J., Kureshi, R., Cardot-Ruffino, V., Agardy, D. A., Ali, L. R., Dougan, J. M., Qiang, L., Shen, J., Zuo, C., Lenehan, P. J., Wang, S. J., Chang, E., Remland, J., Brais, L., Clancy, T. E., Cleary, J. M., Hornick, J. L., Huffman, B. M., …, & Dougan, S. K. (2026). Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. Cancer Cell, 44(7), 1381-1400.e9. https://doi.org/10.1016/j.ccell.2026.04.005

Vancouver

Kureshi CTS, Walsh MJ, Kureshi R, Cardot-Ruffino V, Agardy DA, Ali LR, et al. Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. Cancer Cell. 2026;44(7):1381-1400.e9. doi:10.1016/j.ccell.2026.04.005

BibTeX
@article{Kureshi2026,
  author = {Kureshi, Courtney T S and Walsh, Michael J and Kureshi, Rakeeb and Cardot-Ruffino, Victoire and Agardy, Dennis A and Ali, Lestat R and Dougan, James M and Qiang, Li and Shen, Jiao and Zuo, Chong and Lenehan, Patrick J and Wang, S Jennifer and Chang, Eugena and Remland, Joshua and Brais, Lauren and Clancy, Thomas E and Cleary, James M and Hornick, Jason L and Huffman, Brandon M and Mancias, Joseph D and Molina, George and Fairweather, Mark and Nowak, Jonathan A and Perez, Kimberly J and Rubinson, Douglas A and Slater, Sarah and van Dams, Ritchell and Wang, Jiping and Wolpin, Brian M and Zhao, Lei and Barrientos, Katharine and Novosiadly, Ruslan and Broz, Miranda and Singh, Harshabad and Dougan, Michael and Dougan, Stephanie K},
  title = {Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer},
  journal = {Cancer Cell},
  year = {2026},
  volume = {44},
  number = {7},
  pages = {1381--1400.e9},
  doi = {10.1016/j.ccell.2026.04.005}
}
Kostenlos starten →